Emricasan: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 38 patients with NAFLD, including patients with non-alcoholic steatohepatitis (NASH), showed that twice-daily

Read the full 234 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE